With $30 million in Series A funding, Tranquis Therapeutics launches with a mission of revolutionizing the management of neurodegenerative and aging-related diseases through the advancement of a novel immuno-neurology treatment approach.

Treatments for peanut allergy and Parkinson’s disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show.

LabCorp launched a new test that could assess the capacity of antibodies in patient plasma to inhibit the novel coronavirus.

HyperPointe’s new CEO Ezra T. Ernst began his tenure with a pair of major moves: an agency relaunch and the signing of a new account focused on helping the country move forward from the COVID-19 pandemic.

San Diego-based Engrail Therapeutics launched with $32 million in a Series A financing round that was solely funded by Nan Fung Life Sciences (NFLS).

Full-service health and wellness agency Fingerpaint is forming Photo 51, a new consultancy focused solely on gene and cell therapies.

MJH Life Sciences officially launched Medical World News, a first-of-its-kind 24-hour news program offering insights on the latest news in health care.

LabCorp’s Covance drug development business launched COVID-19 Clinical Trial Connect in the U.S. to help people find information on taking part in clinical trials.

One day after Bristol Myers Squibb announced the commercial launch of the multiple sclerosis drug Zeposia (ozanimod), the company said the medication demonstrated statistically significant efficacy as a potential induction and maintenance therapy for ulcerative colitis.

COVID-19 has changed nearly every aspect of healthcare as we know it. Pharmaceutical commercial organizations must quickly adapt to the present while simultaneously planning for a dramatically different future.